Under the proposed deal, CD&R would acquire a 50% controlling interest in Opella, while Sanofi would retain a substantial stake, positioning itself as a key player in the company’s future ...

Sanofi’s sale of its $17bn consumer health business Opella just advanced a step closer, after the drugmaker signed a share ...